ABEONA THERAPEUTICS INC. Weighted Average Number of Shares, Restricted Stock
ABEONA THERAPEUTICS INC. (ABEO) reported Weighted Average Number of Shares, Restricted Stock of 4.58 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesRestrictedStock · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. weighted average number of shares, restricted stock for the quarter ending 2025-06-30 was 5.13M shares, a 123.50% increase year-over-year.
- ABEONA THERAPEUTICS INC. weighted average number of shares, restricted stock for the quarter ending 2024-06-30 was 2.29M shares.
- ABEONA THERAPEUTICS INC. weighted average number of shares, restricted stock for fiscal 2025 was 4.58M shares.
| Period end | Weighted Average Number of Shares, Restricted Stock 3 month | Weighted Average Number of Shares, Restricted Stock 3 month as first filed | Weighted Average Number of Shares, Restricted Stock 6 month | Weighted Average Number of Shares, Restricted Stock 9 month | Weighted Average Number of Shares, Restricted Stock 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 4.58M shares 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 4.74M shares 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 5.13M shares 10-Q · filed 2026-08-13 | 4.96M shares 10-Q · filed 2026-08-13 | |||
| 2024-06-30 | 2.29M shares 10-Q · filed 2025-08-14 | 2.29B shares 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |